Updates

May 22, 2020May 22, 2020
Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations

The U.S. Food and Drug Administration (FDA) has granted conditional approval to Rubraca (rucaparib) for treating patients with metastatic castration-resistant prostate cancer (mCRPC) and ... Read more
May 21, 2020May 22, 2020
FDA Approves Lynparza for mCRPC Patients with Mutations in DNA Repair Genes

The U.S. Food and Drug Administration has approved the oral therapy Lynparza (olaparib) for treating men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations ... Read more
May 15, 2020May 15, 2020
Erleada Add-on Significantly Extends Survival in Non-metastatic CRPC, SPARTAN Analysis Shows

Adding Erleada (apalutamide) to androgen deprivation therapy (ADT) significantly extends the lives of men with non-metastatic castration-resistant prostate cancer (CRPC) by more than one year, ... Read more
May 8, 2020May 8, 2020
Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

Men with metastatic castration-resistant prostate cancer (mCRPC) showing evidence of active immune responses in their tumors live longer without disease progression after being treated ... Read more
April 29, 2020April 29, 2020
Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

FFF Enterprises and BioNews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

September 12, 2017September 12, 2017

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

News

Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European ... Read more

Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations

FDA Approves Lynparza for mCRPC Patients with Mutations in DNA Repair Genes

Erleada Add-on Significantly Extends Survival in Non-metastatic CRPC, SPARTAN Analysis Shows

Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

FDA Asked to Approve Relugolix to Treat Advanced Prostate Cancer

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

Gene Variant Seen to Promote Castration-resistant Disease in Whites

Winners Named for Prostate Cancer Foundation’s TRUE Love Awareness Contest

Guidelines for Radiation Therapy with COVID-19 Urge Less Treatment

Subscribe to our mailing list

Combining Two Biopsy Methods Improves PC Diagnosis, Study Shows

Urine Biomarkers Can Be Used to Develop Test for Prostate Cancer, Study Finds

Proscia and UCSF Partnering to Deliver AI Apps to Improve Cancer Diagnosis

Veru Advances Prostate Cancer Therapy VERU-111 to Phase 2 Portion of Trial

Adoptive Cell Therapy Can Slow Prostate Cancer Growth, Study in Mice Reports

Ciforadenant Has Promising Anti-tumor Activity in mCRPC, Early Data Show

Prolaris Test Predicts Which PC Patients Benefit from Combo Therapy, Study Finds

3 New miR Scientific Urine Tests Diagnose, Classify Prostate Cancer, Data Shows

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery

Statins, Metformin May Extend Survival in High-risk Prostate Cancer, Large Study Suggests

Decipher GRID ‘Signature’ Predicts Chemo Benefits in HSPC, Research Shows

High Vegetable Diet Does Not Halt Prostate Cancer, Study Finds

Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

Adding Provenge to Xtandi, Zytiga Reduces Risk of Death by 45% in mCRPC Patients, Data Shows

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

eRapa Leads to Boost in Immune Cells in Low-Grade Prostate Cancer Patients, Phase 1b Data Suggest

UPenn Researchers Awarded $500K Grant to Develop CAR T-cell Therapy for Advanced PC

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

Concerto, Pfizer Expand Data Partnership to Include Prostate, Other Cancers

Stony Brook Team Given $4.2M Grant to Expand Promising Work in Advanced Prostate Cancer

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer

First Patient Dosed in Early Trial Testing ORIC-101, Xtandi Combo for Metastatic Prostate Cancer

DNA Non-coding Regions Identified as Therapeutic Targets for Prostate Cancer, New Study Suggests

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

FDA OKs Phase 2b Trial on SUBA-Itraconazole for Metastatic Castration-resistant Prostate Cancer

FDA Grants Priority Review to Lynparza as Treatment for Mutated Metastatic Castration-resistant Prostate Cancer

Zuclomiphene Safely Eases Hot Flashes Linked to ADT Use, Phase 2 Trial Reports

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations

Advaxis Seeks FDA Approval to Begin Phase 1 Trial of its ADXS-504 Immunotherapy for Prostate Cancer

Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests

Pin It on Pinterest